Fintel reports that on February 17, 2026, Citigroup initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation.
Analyst Price Forecast Suggests 184.02% Upside
As of February 4, 2026, the average one-year price target for Cullinan Therapeutics is $32.92/share. The forecasts range from a low of $22.22 to a high of $55.65. The average price target represents an increase of 184.02% from its latest reported closing price of $11.59 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cullinan Therapeutics is 153MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.19.
What is the Fund Sentiment?
There are 258 funds or institutions reporting positions in Cullinan Therapeutics. This is an decrease of 44 owner(s) or 14.57% in the last quarter. Average portfolio weight of all funds dedicated to CGEM is 0.11%, an increase of 12.93%. Total shares owned by institutions decreased in the last three months by 1.08% to 68,127K shares. 
The put/call ratio of CGEM is 0.41, indicating a bullish outlook.
What are Other Shareholders Doing?
Lynx1 Capital Management holds 8,964K shares representing 15.17% ownership of the company. In its prior filing, the firm reported owning 5,766K shares , representing an increase of 35.67%. The firm increased its portfolio allocation in CGEM by 169.84% over the last quarter.
MPM Oncology Impact Management holds 7,648K shares representing 12.95% ownership of the company. No change in the last quarter.
Bvf holds 5,751K shares representing 9.73% ownership of the company. No change in the last quarter.
Kynam Capital Management holds 3,114K shares representing 5.27% ownership of the company. In its prior filing, the firm reported owning 2,302K shares , representing an increase of 26.07%. The firm increased its portfolio allocation in CGEM by 102.56% over the last quarter.
Deerfield Management Company, L.p. holds 2,927K shares representing 4.95% ownership of the company. In its prior filing, the firm reported owning 3,856K shares , representing a decrease of 31.72%. The firm decreased its portfolio allocation in CGEM by 49.71% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
